Ana Ruiz Garcia, Pharm.D, Ph.D

Group Leader, Senior Principal Scientist I

Ana has over 18 years of industry drug development experience working with small and large molecules, mainly focused in the therapeutic areas of Oncology and Inflammation.  Ana has worked in the quantitative and regulatory aspects of many successful NDA/BLA submissions. Ana’s areas of expertise include characterization of drug myelosuppression, tumor growth inhibition and absorption models.

Recent publications by this scientist

Pharmacometric Dose Optimization of Buprenorphine in Neonatal Opioid Withdrawal Syndrome

June 3, 2021

Eudy-Byrne, R., Zane, N., Adeniyi-Jones, S.C., Gastonguay, M.R., Ruiz-Garcia, A., Kushal, G. and Kraft, W.K. (2021). Clinical and Translational Science. Accepted Author Manuscript. https://doi.org/10.1111/cts.13074

View More

Modeling and simulation of lumefantrine pharmacokinetics in HIV-infected and HIV-uninfected children with malaria and the role of lumefantrine exposure as a potential driver of drug resistance

November 16, 2020

Kay K, Goodwin J, Mwebaza N, Ruiz A, Ehrlich H, Ou J, Freeman T, Wade M, Huang L, Wang K, Li F, Aweeka FT, Riggs M, Kajubi R, Parikh S.  Presented at the annual meeting of the American Society of Tropical Medicine and Hygiene, October 16-18, 2020.

Download PDF